Loading…
Onyx Biotec (ONYX)₹34.00−1.73%Pharmaceuticals
In the Mar 2026 quarter (standalone), Onyx Biotec reported sales of ₹34.89 Cr, up 9.8% from Mar 2025, and net profit of ₹0.70 Cr, down 64.6% year on year. For the year to Mar 2026, sales were ₹69.49 Cr and net profit −₹0.22 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 23.87 | 29.85 | 30.14 | 31.79 | 34.61 | 34.89 |
| Expenses | 20.50 | 24.97 | 24.47 | 27.19 | 33.68 | 32.45 |
| Operating Profit | 3.43 | 4.92 | 5.72 | 4.64 | 0.95 | 2.46 |
| OPM % | 14.3% | 16.4% | 18.9% | 14.5% | 2.7% | 7.0% |
| Other Income | 0.03 | 0.08 | 0.98 | 0.17 | 0.23 | 0.20 |
| Interest | 0.82 | 1.26 | 1.35 | 0.61 | 0.54 | 0.65 |
| Depreciation | 0.74 | 1.15 | 1.54 | 1.52 | 1.57 | 1.50 |
| Profit before tax | 1.91 | 2.60 | 3.82 | 2.69 | −0.94 | 0.52 |
| Tax % | 15.3% | 21.3% | 21.6% | 26.2% | −3.2% | −35.3% |
| Net Profit | 1.61 | 2.04 | 3.00 | 1.98 | −0.91 | 0.70 |
| EPS (Rs) | 2.70 | 1.51 | 2.23 | 1.10 | −0.49 | 0.37 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 44.85 | 39.48 | 53.74 | 61.94 | 69.49 |
| Expenses | 39.14 | 35.01 | 45.40 | 51.61 | 66.11 |
| Operating Profit | 5.78 | 4.51 | 8.41 | 10.41 | 3.41 |
| OPM % | 12.8% | 11.3% | 15.5% | 16.7% | 4.9% |
| Other Income | 0.11 | 0.10 | 0.12 | 1.16 | 0.43 |
| Interest | 0.64 | 0.56 | 2.15 | 2.01 | 1.20 |
| Depreciation | 1.46 | 1.50 | 1.88 | 3.06 | 3.06 |
| Profit before tax | 3.80 | 2.56 | 4.50 | 6.49 | −0.43 |
| Tax % | 11.6% | 27.5% | 19.2% | 23.5% | −50.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| Net Profit | 3.36 | 1.85 | 3.64 | 4.96 | −0.22 |
| EPS (Rs) | 5.69 | 3.13 | 2.71 | 2.74 | −0.11 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 13.32 | 18.15 | 18.14 |
| Reserves | 10.44 | 12.25 | 11.92 | 37.34 | 37.15 |
| Borrowings | 12.27 | 29.25 | 30.81 | 12.49 | 15.22 |
| Other Liabilities | 8.18 | 11.25 | 17.98 | 23.16 | 24.49 |
| Total Liabilities | 36.79 | 58.65 | 74.03 | 91.14 | 95.00 |
| Fixed Assets | 17.24 | 42.45 | 43.44 | 40.89 | 39.15 |
| CWIP | 4.00 | 0.00 | 0.00 | 0.00 | 3.67 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 15.55 | 16.20 | 30.59 | 50.25 | 52.18 |
| Inventories | 3.06 | 6.34 | 9.12 | 16.13 | 14.06 |
| Trade receivables | 8.43 | 5.09 | 15.41 | 20.27 | 27.55 |
| Cash & equivalents | 0.02 | 0.02 | 1.48 | 8.64 | 4.05 |
| Total Assets | 36.79 | 58.65 | 74.03 | 91.14 | 95.00 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 0.50 | 1.97 | 1.53 | 1.43 | −1.50 |
| Cash from investing activity | −5.77 | −22.63 | −3.14 | 0.65 | −4.57 |
| Cash from financing activity | 5.21 | 16.46 | 3.10 | 5.08 | 1.51 |
| Net cash flow | −0.08 | −4.29 | 1.45 | 7.13 | −4.56 |
| Capex | 5.78 | 22.75 | 3.23 | 1.04 | 4.98 |
| Free cash flow | −5.28 | −20.72 | −1.69 | 1.90 | −6.46 |
| CFO / OP % | 8.0% | 44.0% | 18.0% | 14.0% | −44.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 68 | 46 | 103 | 118 | 143 |
| Inventory days | 43 | 111 | 94 | 151 | 100 |
| Days payable | 59 | 120 | 141 | 156 | 125 |
| Cash conversion cycle | 51 | 37 | 56 | 113 | 119 |
| Working capital days | 36 | −52 | 38 | 87 | 77 |
| ROCE % | — | 8.2% | 12.9% | 12.2% | 1.1% |
For the Mar 2026 quarter, Onyx Biotec reported sales of ₹34.89 Cr, up 9.8% year on year and net profit of ₹0.70 Cr, down 64.6% year on year. The operating margin was 7.0%.
Onyx Biotec's sales for the year to Mar 2026 were ₹69.49 Cr.
Net profit for the year to Mar 2026 was −₹0.22 Cr. Earnings per share over the same trailing period were ₹−0.11.
Onyx Biotec reported borrowings of ₹15.22 Cr at Mar 2026, against cash and equivalents of ₹4.05 Cr.
Cash from operations was −₹1.50 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹6.46 Cr.